Element Nutritional Sciences Inc (TSE:MUSL) has released an update.
Promino Nutritional Sciences Inc. has initiated a preclinical trial led by Dr. Patrick Gunning to test the effectiveness of its Promino™ product in preserving muscle mass for cancer patients during intense chemotherapy. If successful, the company plans to develop a specialized version for the North American healthcare market. Additionally, Promino has recently achieved milestones in retail partnerships, production, and clinical results, underscoring its growing presence in the nutritional supplement industry.
For further insights into TSE:MUSL stock, check out TipRanks’ Stock Analysis page.
